What is the recommended treatment approach for hidradenitis suppurativa?

Hidradenitis Suppurativa Treatment Approach

Begin with oral clindamycin 300 mg twice daily plus rifampicin 300–600 mg daily for 10–12 weeks, combined with intralesional triamcinolone 10 mg/mL injected into acutely inflamed nodules for rapid symptom relief. This regimen achieves response rates of 71–93% and is the most effective first-line systemic therapy for moderate hidradenitis suppurativa. 1, 2

Initial Disease Severity Assessment

• Determine Hurley stage by examining all intertriginous areas (axillae, groin, perineum, inframammary folds, buttocks) for isolated nodules/abscesses (Stage I), recurrent nodules with limited sinus tracts (Stage II), or extensive sinus tracts and scarring (Stage III). 1, 2
• Document baseline pain using a 0–10 Visual Analog Scale; severe pain is a cardinal symptom requiring aggressive management. 1, 2
• Count inflammatory lesions (nodules + abscesses) to establish a baseline for monitoring HiSCR (≥50% reduction without new abscesses or draining fistulas). 1, 2
• Screen immediately for comorbidities: depression/anxiety (higher rates than general population), diabetes (1.5–3-fold increased risk), hypertension, hyperlipidemia, and inflammatory bowel disease (especially Crohn disease). 1, 2

Treatment Algorithm by Hurley Stage

Hurley Stage I (Mild Disease)

• Topical clindamycin 1% solution or gel applied twice daily to all affected areas for 12 weeks. 1, 2
• Combine with benzoyl peroxide wash (chlorhexidine 4% or benzoyl peroxide 10%) to reduce Staphylococcus aureus resistance risk. 1, 2, 3
• Intralesional triamcinolone 10 mg/mL (0.2–2.0 mL per lesion) for acutely inflamed nodules provides rapid relief within 24 hours with significant reductions in erythema, edema, suppuration, and pain. 1, 2

Hurley Stage II (Moderate Disease)

• First-line regimen: Clindamycin 300 mg orally twice daily PLUS rifampicin 300–600 mg orally once or twice daily for 10–12 weeks. This combination is markedly superior to tetracycline monotherapy (71–93% response vs. 30% abscess reduction). 1, 2
• Add intralesional triamcinolone 10 mg/mL to all inflamed nodules and abscesses for immediate symptom control. 1, 2
• Alternative for widespread mild disease without deep abscesses: Doxycycline 100 mg once or twice daily for 12 weeks, but this is NOT first-line for Stage II with abscesses due to minimal effect on deep inflammatory lesions. 1, 2

Hurley Stage III (Severe Disease)

• Adalimumab dosing: 160 mg subcutaneous at week 0,80 mg at week 2, then 40 mg weekly (NOT every other week) starting at week 4. 1, 2
• HiSCR response rates: 42–59% at week 12 in placebo-controlled trials. 1
• Bridge therapy while awaiting biologic approval: Clindamycin 300 mg + rifampicin 300 mg twice daily. 1, 2
• Consider combining adalimumab with surgical excision for greater clinical effectiveness than adalimumab monotherapy. 1, 2

12-Week Reassessment and Escalation

• Reassess at 12 weeks using pain VAS, inflammatory lesion count, number of flares, and Dermatology Life Quality Index (DLQI). 1, 2
• Measure HiSCR: ≥50% reduction in abscess/nodule count with no increase in abscesses or draining fistulas. 1, 2
• If no response after 12 weeks of clindamycin-rifampicin, escalate directly to adalimumab. 1, 2
• If adalimumab fails after 16 weeks, consider second-line biologics: infliximab 5 mg/kg (weeks 0,2,6, then every 2 months), secukinumab (64.5–71.4% response in adalimumab-failure patients), or ustekinumab. 1, 2

Mandatory Adjunctive Measures (All Stages)

• Smoking cessation referral: 70–75% of HS patients smoke; tobacco use worsens outcomes and increases treatment failure. 1, 2
• Weight management referral: Obesity prevalence exceeds 75% in HS; weight loss improves disease control. 1, 2
• Pain management with NSAIDs for symptomatic relief. 1, 2
• Appropriate wound dressings for draining lesions (absorptive foam or hydro-fiber dressings preferred over petroleum-based). 1, 2

Surgical Considerations

• Radical wide excision for extensive disease with sinus tracts and scarring after failure of systemic therapy; achieves non-recurrence rates of approximately 81%. 1, 2
• Wound closure options: secondary intention healing, split-thickness skin grafts, or local flaps (e.g., thoracodorsal artery perforator flap). 1
• Deroofing for recurrent nodules and sinus-tract tunnels as a targeted procedure. 1, 2

Critical Pitfalls to Avoid

• Do NOT use doxycycline or tetracycline monotherapy as first-line for Hurley Stage II with abscesses; these have minimal effect on deep inflammatory lesions (only 30% abscess reduction). 1, 2
• Do NOT prescribe adalimumab 40 mg every other week; weekly dosing is required for efficacy. 1, 2
• Do NOT extend antibiotics beyond 12 weeks without formal reassessment; prolonged use increases antimicrobial resistance without proven additional benefit. 1, 2
• Do NOT use topical clindamycin alone for Hurley Stage II; it only reduces superficial pustules, not inflammatory nodules or abscesses. 1, 2
• Implement treatment breaks after completing 10–12 week antibiotic courses to assess need for ongoing therapy and limit antimicrobial resistance risk. 1, 2